A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). (Q46055629)

19 December 2017

title

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). (English)

1 reference

19 December 2017

0 references

2

Joan T Merrill

1 reference

19 December 2017

Kenneth C. Kalunian

1

object named as

Kenneth C Kalunian

1 reference

19 December 2017

author name string

Romeo Maciuca

3

1 reference

19 December 2017

Jacqueline M McBride

4

1 reference

19 December 2017

Michael J Townsend

5

1 reference

19 December 2017

Xiaohui Wei

6

1 reference

19 December 2017

John C Davis

7

1 reference

19 December 2017

William P Kennedy

8

1 reference

19 December 2017

language of work or name

English

0 references

publication date

2 June 2015

1 reference

19 December 2017

Annals of the Rheumatic Diseases

published in

1 reference

19 December 2017

volume

75

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

196-202

1 reference

19 December 2017

Systemic lupus erythematosus.

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Systemic lupus erythematosus: an update on current pharmacotherapy and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Type I interferon and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

The type I interferon system in the etiopathogenesis of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Immune Interferon in the Circulation of Patients with Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Type I interferon correlates with serological and clinical manifestations of SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Recent insights into the genetic basis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

The genetics of systemic lupus erythematosus and implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Type I interferon and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Optimization of current and future therapy for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

Numerical scoring for the BILAG-2004 index

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206090

10.1136/ANNRHEUMDIS-2014-206090

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017